Literature DB >> 25823959

Psychological aspects of hyperandrogenic states in late adolescent and young women.

Jenny Guidi1, Alessandra Gambineri2, Laura Zanotti2, Flaminia Fanelli2, Giovanni A Fava1, Renato Pasquali2.   

Abstract

OBJECTIVE: The psychosocial implications of polycystic ovary syndrome (PCOS) phenotypes have been investigated in different patient populations, but little attention was paid to adolescent and young women. The aim of this study was to evaluate the psychosocial correlates of PCOS and other hyperandrogenic states in a population of late adolescent and young females and to provide a psychological characterization of specific clinical hyperandrogenic phenotypes.
DESIGN: This was a cross-sectional study. PATIENTS: High school female students, aged 16-19 years. MEASUREMENTS: The study protocol was designed with three possible levels of participation characterized by an increased level of commitment. For the specific purposes of this investigation, we focused on the subsamples of students whose clinical state was assessed by medical examination (n = 835) and for whom additional laboratory tests were available (n = 394). Psychological evaluation encompassed psychological distress, levels of stress, well-being, illness behaviour and quality of life (as measured by the Symptom Questionnaire, the Psychosocial Index and the Psychological Well-Being scales).
RESULTS: Significantly higher levels of psychological distress and impaired well-being and quality of life were found among late adolescent and young women with isolated clinical hyperandrogenism compared to their normal counterparts. Furthermore, females with PCOS showed significantly greater hostility/irritability compared to healthy control subjects.
CONCLUSIONS: These findings highlight the importance of early recognizing and adequately managing psychological distress in such patients.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 25823959     DOI: 10.1111/cen.12783

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

Review 1.  New perspectives on the definition and management of polycystic ovary syndrome.

Authors:  R Pasquali; A Gambineri
Journal:  J Endocrinol Invest       Date:  2018-01-23       Impact factor: 4.256

2.  COVID-19 Vaccine Hesitancy Among Older Adolescents and Young Adults: A National Cross-Sectional Study in China.

Authors:  Panpan Zhang; Yan Li; Huanchun Wang; Liyan Luo; Ping Wang; Huimin Wang; Qing Li; Zejing Meng; Hui Yang; Yuanhong Liu; Shiyue Zhou; Nan Li; Shengnan Zhang; Jianzhong Bi; Jiewen Zhang; Xiaolei Zheng
Journal:  Front Public Health       Date:  2022-05-12

Review 3.  Contemporary approaches to the management of polycystic ovary syndrome.

Authors:  Renato Pasquali
Journal:  Ther Adv Endocrinol Metab       Date:  2018-02-07       Impact factor: 3.565

4.  The evaluation of the relationship between some related hormone levels and diet in obese or overweight patients with hirsutism: A randomized clinical trial.

Authors:  Atefeh Krouni; Sedighe Forouhari; Bahia Namavarjahromi; Mohammad Hossein Dabbaghmanesh; Arezoo Shayan; Sara Sepasi; Atefeh Zare
Journal:  J Family Med Prim Care       Date:  2017 Oct-Dec

Review 5.  Measures of health-related quality of life in PCOS women: a systematic review.

Authors:  Zahra Behboodi Moghadam; Bita Fereidooni; Mohsen Saffari; Ali Montazeri
Journal:  Int J Womens Health       Date:  2018-08-01

6.  Assessing Whether Meditation Improves Quality of Life for Adolescent Girls With Polycystic Ovary Syndrome: Protocol for a Randomized Controlled Trial.

Authors:  Erandi Hewawasam; Leah Brennan; Lynne Giles; Mary Louise Hull; Asha Short; Robert Norman; Alexia S Peña
Journal:  JMIR Res Protoc       Date:  2020-01-28

Review 7.  Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions.

Authors:  Antonio Aversa; Sandro La Vignera; Rocco Rago; Alessandra Gambineri; Rossella E Nappi; Aldo E Calogero; Alberto Ferlin
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-11       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.